„It is more important to know what sort of person has a disease than to know what sort of disease a person has”. Today, 2.400 years later, science is reviving this idea of Hippocrates: The ever more proceeding medical-technical progress is the basis for personalized medicine. In-vitro diagnostics are its value drivers. Their development requires diverse subject-specific expertises that only networks are able to supply in the necessary broadness.
The Companion Diagnostics Network develops in-vitro diagnostics for
- pharmaceuticals that are currently in the pipeline
- pharmaceuticals that are already on the market
- agents that have failed approval
Highly specialized partners take a stake in the network covering the whole technology spectrum. Renowned partners with expertises in the area of certification, approval, reimbursement and patent law complete the portfolio.
Reliability & Security
The network offers security through stable structures and through their member companies that have established themselves on the market for many years. In addition, due to the foundation of the Diagnostik-BB GmbH customers will have a credible partner on their side accompanying all phases of the project.
Paramount Quality Standards & Cost Advantages
All member companies are certified according to the required ISO norms and hence guarantee quality. Moreover, a minor administrative effort through one contact person for all requests and an efficient as well as flexible use of resources within the network result in cost advantages.
Swiftness & Flexibility
The medium-sized structure ensures short decision-making processes and flexible response toward the customer‘s requests. A network management that is actively imbedded in the whole process facilitates an interdisciplinary collaboration without loss of time and efficiency.
The network’s companies operate worldwide. They possess a global network of distribution partners or own subsidiaries in Europe, Asia as well as in North and South America.
Confidentiality is an obligation.
no news in this list.
Individualized therapies through novel diagnostics